Non-Executive Board Change

Stem Cell Sciences plc
04 February 2008



Press Release

                               Stem Cell Sciences

                           NON-EXECUTIVE BOARD CHANGE
                         ("Stem Cell Sciences", "SCS")

4th February 2008

Stem Cell Sciences plc (AIM:STEM, ASX:STC) today announced that non-executive
Director Jeremy Paul Scudamore, due to the increasing work load from his other
non-executive positions, has reluctantly retired from the Board of SCS effective
January 31, 2008

The Board of SCS would like to thank Mr Scudamore for his considerable
contribution to the company and wish him well with his new endeavours.

                                    - Ends -

For further information, please contact:

Stem Cell Sciences plc (United Kingdom)
Alastair Riddell CEO
[phone]

Halsin Partners (United Kingdom)
Michael Sinclair, Director
[phone]

Talk Biotech (Australia)
Fay Weston
[phone]

Notes to Editors
Stem Cell Sciences plc (SCS, AIM:STEM, ASX:STC) is a global biotechnology
company providing the biological infrastructure of cells and cell culture media
to the burgeoning stem cell research market.

Stem Cell Sciences' core objective is to develop safe and effective cell-based
therapies for currently incurable diseases. SCS retains all rights to its
technology for therapeutic use and is targeting cell-based therapies for
neurodegenerative disease and injury.

Revenues from Stem Cell Sciences' research business are delivered via an
integrated network of business teams and regional offices in Edinburgh and
Cambridge (UK), Melbourne (Australia) and San Francisco (USA). This global reach
provides the Company with the direct access to markets through experienced
personnel and local business networks needed to drive SCS business growth in
each region.

The key challenge for the successful application of stem cells in both research
and clinical applications is the reproducible supply of pure, fully
characterised stem cells and stem cell-derived specialised cells such as nerves
and muscle. This represents a significant technological challenge that will
require access to multiple technologies and a globally integrated stem cell
initiative.

To access cutting edge technologies on a rapid and on-going basis, Stem Cell
Sciences has built an exceptional network of highly interactive collaborations
with academic centres of excellence in the stem cell field. These collaborations
have been the source of our founding technologies and continue to provide an
expanding pipeline of products and intellectual property that are central to the
Company's strategy and success.

To facilitate research and technology transfer with its major collaborating
academic institutions, Stem Cell Sciences' business and scientific teams are
usually co-located on site or adjacent to the centre of excellence in
independent company facilities. The Company's key collaborating institutes
include the Wellcome Trust Centre for Stem Cell Research (University of
Cambridge), the Institute of Stem Cell Research (University of Edinburgh), RIKEN
Centre for Developmental Biology (Kobe) and the Australian Stem Cell Centre
(Melbourne).

Academic and commercial use of stem cells in basic research and drug discovery
provides the Company with immediate and growing revenue streams and offsets the
cost of technology development for full scale cell production of SCS cell-based
therapeutics.

For further information on the company please visit: www.stemcellsciences.com




                      This information is provided by RNS
            The company news service from the London Stock Exchange